Journal Cover Nature Reviews Drug Discovery
  [SJR: 11.742]   [H-I: 235]   [337 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
   Published by NPG Homepage  [142 journals]
  • RNA-modifying proteins as anticancer drug targets
    • RNA-modifying proteins as anticancer drug targets

      RNA-modifying proteins as anticancer drug targets, Published online: 18 May 2018; doi:10.1038/nrd.2018.71

      Covalent modifications of RNA — mediated by RNA-modifying proteins (RMPs) — affect RNA stability and translation to proteins, and some of these RMPs have been implicated in cancer. Here, Copeland and colleagues review the current understanding of RNA modifications with a focus on mRNA methylation and assess the potential of RMPs as novel anticancer targets.RNA-modifying proteins as anticancer drug targets, Published online: 2018-05-18; doi:10.1038/nrd.2018.712018-05-18
      DOI: 10.1038/nrd.2018.71
       
  • Neuroscience: Reconnecting the brain after injury
    • Neuroscience: Reconnecting the brain after injury

      Neuroscience: Reconnecting the brain after injury, Published online: 18 May 2018; doi:10.1038/nrd.2018.83

      Neuroscience: Reconnecting the brain after injuryNeuroscience: Reconnecting the brain after injury, Published online: 2018-05-18; doi:10.1038/nrd.2018.832018-05-18
      DOI: 10.1038/nrd.2018.83
       
  • The haemophilia drug market
    • The haemophilia drug market

      The haemophilia drug market, Published online: 18 May 2018; doi:10.1038/nrd.2018.54

      This article discusses the market for therapies for haemophila, which is forecast to change substantially with the recent launch of emicizumab and the potential future approvals of gene therapies and non-factor treatments.The haemophilia drug market, Published online: 2018-05-18; doi:10.1038/nrd.2018.542018-05-18
      DOI: 10.1038/nrd.2018.54
       
  • Neurodegenerative disorders: Rescuing mitochondrial motility
    • Neurodegenerative disorders: Rescuing mitochondrial motility

      Neurodegenerative disorders: Rescuing mitochondrial motility, Published online: 18 May 2018; doi:10.1038/nrd.2018.76

      Neurodegenerative disorders: Rescuing mitochondrial motilityNeurodegenerative disorders: Rescuing mitochondrial motility, Published online: 2018-05-18; doi:10.1038/nrd.2018.762018-05-18
      DOI: 10.1038/nrd.2018.76
       
  • Antibacterial drugs: Disrupting MRSA 'persisters'
    • Antibacterial drugs: Disrupting MRSA 'persisters'

      Antibacterial drugs: Disrupting MRSA 'persisters', Published online: 18 May 2018; doi:10.1038/nrd.2018.84

      Antibacterial drugs: Disrupting MRSA 'persisters'Antibacterial drugs: Disrupting MRSA 'persisters', Published online: 2018-05-18; doi:10.1038/nrd.2018.842018-05-18
      DOI: 10.1038/nrd.2018.84
       
  • Post-exposure treatments for Ebola and Marburg virus infections
    • Post-exposure treatments for Ebola and Marburg virus infections

      Post-exposure treatments for Ebola and Marburg virus infections, Published online: 04 May 2018; doi:10.1038/nrd.2018.73

      Post-exposure treatments for Ebola and Marburg virus infectionsPost-exposure treatments for Ebola and Marburg virus infections, Published online: 2018-05-04; doi:10.1038/nrd.2018.732018-05-04
      DOI: 10.1038/nrd.2018.73
       
  • Interleukin-6: designing specific therapeutics for a complex cytokine
    • Interleukin-6: designing specific therapeutics for a complex cytokine

      Interleukin-6: designing specific therapeutics for a complex cytokine, Published online: 04 May 2018; doi:10.1038/nrd.2018.45

      Dysregulation of IL-6 signalling is associated with inflammatory and lymphoproliferative disorders, and several classes of therapeutics have been developed that target components of the IL-6 signalling pathway. This Review describes the progress made in recent years in inhibiting IL-6-signalling and analyses the advantages and disadvantages of these approaches.Interleukin-6: designing specific therapeutics for a complex cytokine, Published online: 2018-05-04; doi:10.1038/nrd.2018.452018-05-04
      DOI: 10.1038/nrd.2018.45
       
  • Neurodegeneration: New strategy for SBMA therapy
    • Neurodegeneration: New strategy for SBMA therapy

      Neurodegeneration: New strategy for SBMA therapy, Published online: 27 April 2018; doi:10.1038/nrd.2018.55

      Neurodegeneration: New strategy for SBMA therapyNeurodegeneration: New strategy for SBMA therapy, Published online: 2018-04-27; doi:10.1038/nrd.2018.552018-04-27
      DOI: 10.1038/nrd.2018.55
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.224.108.85
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-